- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00989391
A Study In Healthy People To Investigate The Safety, Toleration And Time Course Of Blood Concentrations Of Multiple Doses Of PF-03654764, Given By Mouth
15 dicembre 2009 aggiornato da: Pfizer
A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03654764 In Healthy Subjects
The purpose of this study in heathy people is to investigate the safety, toleration and time course of PF-03654764 in the blood, following multiple doses given once or twice daily by mouth for 10 days.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
36
Fase
- Fase 1
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Singapore, Singapore, 188770
- Pfizer Investigational Site
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 21 anni a 55 anni (Adulto)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Healthy subjects. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- A positive urine drug screen.
- Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Cohort 1
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
|
Sperimentale: Cohort 2
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
|
Sperimentale: Cohort 3
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
safety & toleration: Adverse events, vital signs, 12 lead ECG, blood and urine safety tests, suicidality assessment using the Suicidality Tracking Scale (STS) and physical examination.
Lasso di tempo: 10 days
|
10 days
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Plasma pharmacokinetics: Cmax, Tmax, AUCtau, t½, AUCtau (Day 10)/AUCtau (Day 1), CL/F
Lasso di tempo: 10 days
|
10 days
|
|
Urine pharmacokinetics: Ae24 & Ae24% (for once daily doses) or Ae12 & Ae12% (for twice daily dose) on Day 10, CLR
Lasso di tempo: 10 days
|
10 days
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 ottobre 2009
Completamento primario (Effettivo)
1 dicembre 2009
Completamento dello studio (Effettivo)
1 dicembre 2009
Date di iscrizione allo studio
Primo inviato
2 ottobre 2009
Primo inviato che soddisfa i criteri di controllo qualità
2 ottobre 2009
Primo Inserito (Stima)
5 ottobre 2009
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
16 dicembre 2009
Ultimo aggiornamento inviato che soddisfa i criteri QC
15 dicembre 2009
Ultimo verificato
1 dicembre 2009
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- B0711002
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
prodotto fabbricato ed esportato dagli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .